$BCRX
BIOCRYST PHARMACEUTICALS INC

2013 Q4 Form 10-Q Financial Statement

#000119312513434942 Filed on November 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $10.57M $2.389M $5.761M
YoY Change 157.67% -58.53% 9.73%
Cost Of Revenue $20.00K $0.00 $110.0K
YoY Change 0.0% -100.0%
Gross Profit $10.55M $2.390M $5.650M
YoY Change 158.58% -57.7% 7.62%
Gross Profit Margin 99.84% 100.04% 98.07%
Selling, General & Admin $2.060M $1.340M $1.590M
YoY Change 6.74% -15.72% -46.1%
% of Gross Profit 19.53% 56.07% 28.14%
Research & Development $14.83M $7.977M $12.07M
YoY Change 33.72% -33.92% -20.05%
% of Gross Profit 140.57% 333.77% 213.66%
Depreciation & Amortization $50.00K $70.00K $130.0K
YoY Change -70.59% -46.15% -27.78%
% of Gross Profit 0.47% 2.93% 2.3%
Operating Expenses $16.88M $7.977M $12.07M
YoY Change 29.65% -33.92% -33.12%
Operating Profit -$6.330M -$6.925M -$8.016M
YoY Change -29.19% -13.61% -37.38%
Interest Expense $910.0K $1.191M $1.166M
YoY Change -352.78% 2.14% -170.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.430M -$8.000M -$9.700M
YoY Change -50.86% -17.53% -32.92%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.429M -$8.001M -$9.700M
YoY Change -50.88% -17.52% -32.92%
Net Earnings / Revenue -51.38% -334.91% -168.37%
Basic Earnings Per Share
Diluted Earnings Per Share -$91.83K -$140.1K -$191.5K
COMMON SHARES
Basic Shares Outstanding 59.09M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.06M $42.59M $41.00M
YoY Change 6.9% 3.88% -6.82%
Cash & Equivalents $21.16M $26.05M $23.96M
Short-Term Investments $16.89M $16.54M $17.10M
Other Short-Term Assets $1.900M $1.900M $1.500M
YoY Change 5.56% 26.67% -31.82%
Inventory $300.0K
Prepaid Expenses
Receivables $2.100M $2.400M $3.800M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $42.12M $46.84M $46.60M
YoY Change 0.34% 0.51% -22.85%
LONG-TERM ASSETS
Property, Plant & Equipment $306.0K $359.0K $800.0K
YoY Change -47.51% -55.13% -42.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.600M $700.0K $2.500M
YoY Change 116.67% -72.0% -84.76%
Other Assets $3.620M $5.075M $14.20M
YoY Change -58.36% -64.26% -0.7%
Total Long-Term Assets $6.745M $6.366M $17.50M
YoY Change -56.37% -63.62% -45.48%
TOTAL ASSETS
Total Short-Term Assets $42.12M $46.84M $46.60M
Total Long-Term Assets $6.745M $6.366M $17.50M
Total Assets $48.87M $53.21M $64.10M
YoY Change -14.93% -17.0% -30.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.174M $1.241M $2.300M
YoY Change 5.03% -46.04% -36.11%
Accrued Expenses $5.742M $7.668M $9.000M
YoY Change -41.76% -14.8% -27.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.26M $13.18M $12.60M
YoY Change -11.43% 4.62% -34.72%
LONG-TERM LIABILITIES
Long-Term Debt $30.00M $30.00M $30.00M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $4.700M $6.600M $11.70M
YoY Change -56.07% -43.59% -31.58%
Total Long-Term Liabilities $34.70M $36.60M $41.70M
YoY Change -14.74% -12.23% -11.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.26M $13.18M $12.60M
Total Long-Term Liabilities $34.70M $36.60M $41.70M
Total Liabilities $50.00M $49.80M $54.30M
YoY Change -13.64% -8.29% -18.35%
SHAREHOLDERS EQUITY
Retained Earnings -$422.7M -$417.3M
YoY Change 7.67%
Common Stock $421.6M $420.7M
YoY Change 7.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.126M $3.410M $9.800M
YoY Change
Total Liabilities & Shareholders Equity $48.87M $53.21M $64.10M
YoY Change -14.93% -17.0% -30.7%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$5.429M -$8.001M -$9.700M
YoY Change -50.88% -17.52% -32.92%
Depreciation, Depletion And Amortization $50.00K $70.00K $130.0K
YoY Change -70.59% -46.15% -27.78%
Cash From Operating Activities -$4.510M -$7.930M -$11.78M
YoY Change -35.85% -32.68% 12.51%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.260M -$5.810M $11.68M
YoY Change -161.92% -149.74% -28.52%
Cash From Investing Activities -$2.260M -$5.810M $11.68M
YoY Change -162.09% -149.74% -28.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $18.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.890M 20.01M 2.130M
YoY Change 490.62% 839.44% -584.09%
NET CHANGE
Cash From Operating Activities -4.510M -7.930M -11.78M
Cash From Investing Activities -2.260M -5.810M 11.68M
Cash From Financing Activities 1.890M 20.01M 2.130M
Net Change In Cash -4.880M 6.270M 2.030M
YoY Change 58.96% 208.87% -62.62%
FREE CASH FLOW
Cash From Operating Activities -$4.510M -$7.930M -$11.78M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow -$4.510M -$7.930M -$11.77M
YoY Change -35.94% -32.63% 12.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Share Price
SharePrice
4.40
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59091393 shares
CY2011Q2 us-gaap Common Stock Value
CommonStockValue
70000000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23959000
CY2013Q3 bcrx Deduction In Interest
DeductionInInterest
2356000
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59091000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59091000 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
1.85
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9124000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
945000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7668000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1241000
CY2013Q3 us-gaap Restructuring Reserve
RestructuringReserve
158000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13182000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
3410000
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
420097000
CY2013Q3 us-gaap Foreign Currency Derivative Liabilities At Fair Value
ForeignCurrencyDerivativeLiabilitiesAtFairValue
1581000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417280000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1539000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
591000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53205000
CY2013Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
30000000
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5032000
CY2013Q3 us-gaap Interest Payable Current
InterestPayableCurrent
2734000
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
16541000
CY2013Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2369000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
46839000
CY2013Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
680000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
17155000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5075000
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
150000
CY2013Q3 us-gaap Assets
Assets
53205000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50893000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50893000 shares
CY2013Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
16541000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26050000
CY2013Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2369000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
17221000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1656000
CY2013Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
73000
CY2013Q3 us-gaap Investments And Cash
InvestmentsAndCash
43421000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6383000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359000
CY2013Q3 bcrx Currency Hedge Agreement Amount
CurrencyHedgeAgreementAmount
1890000
CY2013Q3 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
252000
CY2013Q3 bcrx Net Proceeds From Public Offering
NetProceedsFromPublicOffering
18500000
CY2013Q3 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
65000
CY2013Q3 bcrx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2846000
CY2013Q3 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
680000
CY2013Q3 bcrx Cash Collateral Margin Funds
CashCollateralMarginFunds
1890000
CY2013Q3 bcrx Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
2000
CY2013Q3 bcrx Available For Sale Securities Gross Unrealized Gains Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments
3000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16444000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.09
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8073000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2815000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9860000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3974000
CY2012Q4 us-gaap Restructuring Reserve
RestructuringReserve
1701000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17224000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-454000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
391611000
CY2012Q4 us-gaap Foreign Currency Derivative Liabilities At Fair Value
ForeignCurrencyDerivativeLiabilitiesAtFairValue
4749000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392601000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1392000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
509000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57439000
CY2012Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
30000000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5920000
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1998000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4562000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
41978000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1151000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15775000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8694000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
308000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
14708000
CY2012Q4 us-gaap Assets
Assets
57439000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20891000
CY2012Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
4562000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15859000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1097000
CY2012Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
412000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2012Q4 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
5033000
CY2012Q4 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
57000
CY2012Q4 bcrx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
6573000
CY2012Q4 bcrx Cash Collateral Margin Funds
CashCollateralMarginFunds
5180000
CY2012Q4 bcrx Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2012Q4 bcrx Available For Sale Securities Gross Unrealized Gains Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments
27000
bcrx Write Off Deferred Balance Under License Agreement
WriteOffDeferredBalanceUnderLicenseAgreement
4995000
dei Entity Registrant Name
EntityRegistrantName
BIOCRYST PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000882796
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
53000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
310000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3237000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0090 pure
us-gaap Debt Instrument Date Of First Required Payment1
DebtInstrumentDateOfFirstRequiredPayment1
2011-09-01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22015000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
562000 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
559000
us-gaap Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
34000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Credit Risk</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of no more than 18&#xA0;months. A significant amount of the Company&#x2019;s receivables are due from BARDA/HHS, for which there is no assumed credit risk, or from Shionogi, for which a single royalty payment is remitted within two months of quarterly sales underlying the royalty payment. Accordingly, credit risk for these receivables is considered minimal based upon the nature of the underlying receivable and their timely remittance.</font></p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1624000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1731000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</font></p> </div>
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000 shares
us-gaap Revenues
Revenues
6764000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24704000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
15232000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24383000
us-gaap Interest And Other Income
InterestAndOtherIncome
72000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
47000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2193000
us-gaap Net Income Loss
NetIncomeLoss
-24679000
us-gaap Royalty Revenue
RoyaltyRevenue
2042000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1509000
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
3168000
us-gaap Sales Revenue Net
SalesRevenueNet
6764000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
26000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-158000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5218000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4925000
us-gaap Costs And Expenses
CostsAndExpenses
31147000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3950000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28379000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
124000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-741000
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
3479000
us-gaap Share Based Compensation
ShareBasedCompensation
3479000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5159000
us-gaap Interest Expense
InterestExpense
3536000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23648000
us-gaap Royalty Expense
RoyaltyExpense
81000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1205000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27116000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
us-gaap Proceeds From Sale Of Furniture And Fixtures
ProceedsFromSaleOfFurnitureAndFixtures
50000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1317000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
329000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
13845000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
736000
CY2012Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-572000
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
5761000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
bcrx Weighted Average Shares Outstanding
WeightedAverageSharesOutstanding
53910000 shares
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year One
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearOne
1819000
bcrx Payment Of Foreign Currency Derivative Collateral
PaymentOfForeignCurrencyDerivativeCollateral
-3290000
bcrx Number Of Stock Based Compensation Plan
NumberOfStockBasedCompensationPlan
2 Plan
bcrx Foreign Currency Hedge Termination Fee
ForeignCurrencyHedgeTerminationFee
5850000
bcrx Share Based Compensation Arrangement By Share Based Payment Award Restricted Options Cancelled Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedOptionsCancelledOutstanding
shares
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
533000
bcrx Currency Hedge Premium Payable Period Minimum
CurrencyHedgePremiumPayablePeriodMinimum
2014
bcrx Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Awards Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
1624000 shares
bcrx Currency Hedge Premium Payable Period Maximum
CurrencyHedgePremiumPayablePeriodMaximum
2020
bcrx Share Based Compensation Arrangement By Share Based Payment Award Option Exercised Award Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisedAwardAvailable
shares
bcrx Share Based Compensation Arrangement By Share Based Payment Award Restricted Options Cancelled Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedOptionsCancelledWeightedAverageExercisePrice
bcrx Share Based Compensation Arrangement By Share Based Payment Award Restricted Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedOptionsGrantedWeightedAverageExercisePrice
bcrx Currency Hedge Agreement Termination Period Minimum
CurrencyHedgeAgreementTerminationPeriodMinimum
2016
bcrx Royalty Payments Received
RoyaltyPaymentsReceived
2042000
bcrx Yen Rate Per Dollar
YenRatePerDollar
100 JPY
bcrx Redemption In Percentage Year Two
RedemptionInPercentageYearTwo
1.035 pure
bcrx Share Based Compensation Arrangement By Share Based Payment Award First Vesting Period After Grant Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate
P1Y
bcrx Foreign Currency Hedge Contingent Payment
ForeignCurrencyHedgeContingentPayment
1950000
bcrx Minimum Currency Value Required For Payment Of Premium On Specified Date
MinimumCurrencyValueRequiredForPaymentOfPremiumOnSpecifiedDate
100
bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
4722000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
2561000
bcrx Share Based Compensation Arrangement By Share Based Payment Award Restricted Options Granted Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedOptionsGrantedOutstanding
shares
bcrx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
3237000 shares
bcrx Currency Hedge Agreement Termination Period Maximum
CurrencyHedgeAgreementTerminationPeriodMaximum
2020
bcrx Foreign Currency Hedge Termination Maximum Obligation
ForeignCurrencyHedgeTerminationMaximumObligation
1950000
bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-5120000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
13777000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1591000
CY2012Q3 us-gaap Interest Expense
InterestExpense
1166000
CY2012Q3 us-gaap Royalty Expense
RoyaltyExpense
114000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12072000
us-gaap Revenues
Revenues
22192000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
393000
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
1398000
bcrx License Agreement Termination Notice Period
LicenseAgreementTerminationNoticePeriod
P90D
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17811000
us-gaap Royalty Expense
RoyaltyExpense
114000
bcrx Redemption In Percentage Thereafter
RedemptionInPercentageThereafter
1.000 pure
bcrx Maximum Amount Of Fund To Be Used From Funding Obligation Under Collaborative And Other Research And Development Contracts
MaximumAmountOfFundToBeUsedFromFundingObligationUnderCollaborativeAndOtherResearchAndDevelopmentContracts
12800000
bcrx Royalty Payment Remittance Period
RoyaltyPaymentRemittancePeriod
P2M
bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive
72000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0086 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30367000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1158000 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28028000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
14487000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23193000
us-gaap Interest And Other Income
InterestAndOtherIncome
182000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2063000
us-gaap Net Income Loss
NetIncomeLoss
-28028000
us-gaap Royalty Revenue
RoyaltyRevenue
2848000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9366000
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
3345000
us-gaap Share Based Compensation
ShareBasedCompensation
3345000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7515000
us-gaap Interest Expense
InterestExpense
3486000
CY2012Q3 us-gaap Revenues
Revenues
5761000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9700000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8016000
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-1531000
us-gaap Sales Revenue Net
SalesRevenueNet
22192000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
115000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-325000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3779000
us-gaap Costs And Expenses
CostsAndExpenses
45385000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4897000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16644000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
321000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21238000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40374000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
522000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
461000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
329000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
35515000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-472000
bcrx Interest Reserve Changes In Operating Assets And Liabilities
InterestReserveChangesInOperatingAssetsAndLiabilities
-1742000
bcrx Weighted Average Shares Outstanding
WeightedAverageSharesOutstanding
49001000 shares
bcrx Payment Of Foreign Currency Derivative Collateral
PaymentOfForeignCurrencyDerivativeCollateral
2010000
bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
19344000
bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-2200000
CY2011Q4 bcrx Percentage Reduction In Royalty Under Amended License Agreement
PercentageReductionInRoyaltyUnderAmendedLicenseAgreement
0.5 pure
CY2013Q2 bcrx License Agreement Termination Date
LicenseAgreementTerminationDate
2013-07-28
CY2011Q2 us-gaap Retail Land Sale Receivables Weighted Average Interest Rate
RetailLandSaleReceivablesWeightedAverageInterestRate
0.02 pure
CY2011Q3 bcrx Common Stock Issued And Sales At Market Price
CommonStockIssuedAndSalesAtMarketPrice
70000000
CY2010Q2 bcrx Reduction In Percentage Of Future Payments
ReductionInPercentageOfFuturePayments
0.5 pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1207000 shares
CY2012Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
CY2012Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
54000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-9700000
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
2848000
CY2012Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000
CY2012Q3 bcrx Weighted Average Shares Outstanding
WeightedAverageSharesOutstanding
50661000 shares
CY2012Q3 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
2913000
CY2012Q3 bcrx Royalty Payments Received
RoyaltyPaymentsReceived
2848000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2783000 shares
CY2013Q3 us-gaap Revenues
Revenues
2389000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8005000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6925000
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
18000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-8001000
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
8000
CY2013Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
97000
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
2389000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
9314000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1337000
CY2013Q3 us-gaap Interest Expense
InterestExpense
1191000
CY2013Q3 us-gaap Royalty Expense
RoyaltyExpense
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7977000
CY2013Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
CY2013Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000
CY2013Q3 bcrx Weighted Average Shares Outstanding
WeightedAverageSharesOutstanding
57124000 shares
CY2013Q3 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
2381000
CY2012Q4 us-gaap Restructuring Charges
RestructuringCharges
1759000

Files In Submission

Name View Source Status
0001193125-13-434942-index-headers.html Edgar Link pending
0001193125-13-434942-index.html Edgar Link pending
0001193125-13-434942.txt Edgar Link pending
0001193125-13-434942-xbrl.zip Edgar Link pending
bcrx-20130930.xml Edgar Link completed
bcrx-20130930.xsd Edgar Link pending
bcrx-20130930_cal.xml Edgar Link unprocessable
bcrx-20130930_def.xml Edgar Link unprocessable
bcrx-20130930_lab.xml Edgar Link unprocessable
bcrx-20130930_pre.xml Edgar Link unprocessable
d605961d10q.htm Edgar Link pending
d605961dex101.htm Edgar Link pending
d605961dex102.htm Edgar Link pending
d605961dex311.htm Edgar Link pending
d605961dex312.htm Edgar Link pending
d605961dex321.htm Edgar Link pending
d605961dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g605961g88e58.jpg Edgar Link pending
g605961pic2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending